Eden review

What it is

Eden is an online health company that sells weight-loss, anti-aging, hair and hormone treatments by subscription. For weight loss, a licensed provider reviews your online assessment and may prescribe a GLP-1.

What it prescribes

Eden’s main GLP-1 products are compounded semaglutide and compounded tirzepatide [1], sold under its own “Authentic Eden” name [2]. Its pages note that FDA does not review or approve compounded medications for safety or effectiveness [3]. It also lists brand-name Wegovy, Zepbound, Ozempic and Mounjaro. Ozempic is approved to improve blood sugar in adults with type 2 diabetes [4], and Lilly says Mounjaro is not a weight loss drug [5]; see what each GLP-1 is approved for.

What it costs

Compounded semaglutide costs $99 a month and compounded tirzepatide $129 a month, the same at every dose [1]. The brand-name drugs cost far more through Eden: Wegovy is listed at $1,695 a month [6] and Zepbound at $1,399 a month [7]. For comparison, Lilly’s own LillyDirect pharmacy lists Zepbound starting at $299 a month for the starting dose [8], and our brand-name cash price guide compares other direct prices.

Eden advertises a money-back “weight loss warranty” if you follow the plan and do not lose at least 15% in 6 months [9]; the conditions are in its terms, so read them before counting on it. Eden does not accept any commercial insurance and is not enrolled in Medicare or Medicaid [10].

Signing up and cancelling

Plans are subscriptions that you can cancel at any time [11]. To avoid paying for the next shipment, the cancellation has to go through before your next billing date [12]. Eden says it serves GLP-1 programs in all 50 states [13].

Safety and regulatory record

FDA reviewed Eden’s website in March 2026 [14] and sent it a warning letter dated June 8, 2026 [15]. The letter said the compounded products on its site carried Eden’s name on the pictured label, suggesting Eden made them when it did not [16]. It also objected to the claim that the drugs came from “FDA-licensed” outsourcing facilities [17]. FDA asked for a written response within 15 business days [18].

Eden’s GLP-1 page still sells “Authentic Eden” medication and now says “We make them,” prepared in its U.S. pharmacy network [2]. FDA issues a close-out letter only after it has checked a company’s corrective actions [19]. When we checked FDA’s warning letter database for this review, no close-out letter was listed for Eden, so we treat the letter as unresolved and do not link to Eden.

Who it suits, and who should look elsewhere

Eden suits a cash buyer who wants a low, flat price for a compounded GLP-1 and accepts both that FDA has not approved it and that FDA has an open warning letter about the company’s marketing. If you want brand-name Zepbound, Eden’s price is several times what Lilly’s own self-pay pharmacy charges for the starting dose [7] [8]. Start with our brand-name cash price guide or program comparison.